Navigation Links
Rigel to Present at BIO CEO & Investor Conference
Date:2/7/2013

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower , the company's chairman and chief executive officer, is scheduled to present a company overview at the 15th Annual BIO CEO & Investor Conference in New York City on Monday, February 11th at 10:00 a.m. ET.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.

Contact: Ryan Maynard    
Phone: 650.624.1284    
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
9. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt Join the ... software solutions for life sciences, today announced key new leaders have ... insight to a growing business.  This will bolster the company,s safety ... joined ArisGlobal in the position of Vice President - Safety. ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... ... Each year, about 800,000 people suffer from cerebral vascular accidents, or strokes. ... for one death every four minutes. Many people who survive a stroke are ... a video series called “Your Brain,” in conjunction with its medical journal “Balance,” in ...
(Date:5/3/2016)... Toronto, ON (PRWEB) , ... May 03, 2016 ... ... been recognized as one of Canada’s top Information and Communication Technology (ICT) companies ... top Canadian and Multinational ICT companies operating in Canada, as ranked by revenue. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Branches, Inc. ... its Grow & Climb children and youth programs in South Miami. Macy’s is a ... , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic support to ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... healthcare organizations, especially medium and small physician practices, to better grasp and implement ... step-by-step approach that guides practices on a well-defined, expert-created path to compliance. HIPAA ...
(Date:5/2/2016)... Denver, CO (PRWEB) , ... May 02, 2016 , ... ... will serve as the keynote speaker for five events throughout the month of May. ... for a number of national news outlets. He also frequently appears on the Science ...
Breaking Medicine News(10 mins):